Is HbA1c an ideal biomarker of well-controlled diabetes?

2020/09/10 by Georgia Kaiafa, Stavroula Veneti, George Polychronopoulos +6
Medicine · Biochemistry, Genetics and Molecular Biology · #Diabetes Management and Research #Diabetes and associated disorders #Hyperglycemia and glycemic control in critically ill and hospitalized patients

paper · pdf · doi:10.1136/postgradmedj-2020-138756

Abstract

HbA1c is a biomarker with a central role in the diagnosis and follow-up of patients with diabetes, although not a perfect one. Common comorbidities encountered in patients with diabetes mellitus, such as renal insufficiency, high output states (iron deficiency anaemia, haemolytic anaemia, haemoglobinopathies and pregnancy) and intake of specific drugs could compromise the sensitivity and specificity of the biomarker. COVID-19 pandemic poses a pressing challenge for the diabetic population, since maintaining optimal blood glucose control is key to reduce morbidity and mortality rates. Alternative methods for diabetes management, such as fructosamine, glycosylated albumin and device-based continuous glucose monitoring, are discussed.

Citations

• Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c

Related

• Glycosylated Haemoglobin: Determinants and Metabolic Correlates in T2DM in a Semi-Urban Nigeria Setting. A Prospective Study.
• International Consensus on Use of Continuous Glucose Monitoring
• Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with Type 2 diabetes: projections of effectiveness from a regression model
• Prevalence of Undiagnosed and Suboptimally Controlled Diabetes by Point‐of‐care HbA1C in Unselected Emergency Department Patients
• The ambulatory glucose profile and its interpretation